Benefits of Standard-of-Care Established in Patients with Morphea
Standard-of-care therapy appears to improve disease activity in patients with morphea, according to a long-term follow-up study.
In this prospective cohort study, 130 patients with morphea from the Morphea in Adults and Children cohort were followed for ≥2 years. Mean (SD) follow-up was 4.3 (1.7) years, with 50 patients followed for ≥5 years.
Overall, 55% of patients had linear subtype and 31% had generalized subtype. In patients with generalized subtype, 43% had recurrence of disease activity whereas 21% of patients with linear subtype had recurrence of disease activity.
Time to first recurrence of disease activity after initial resolution of disease activity was 1.1 (0.8-1.9) years in patients with generalized subtype and 2.3 (1.0-3.3) years in patients with linear subtype.
In the patients with ≥5 years follow up, 36% had recurrence of disease activity.
Standard-of-care improved disease activity in most patients over 6 to 12 months, the authors concluded.
O’Brien JC, Nymeyer H, Green A, Jacobe HT. Changes in disease activity and damage over time in patients with morphea. JAMA Dermatol. Published online April 01, 2020. doi:10.1001/jamadermatol.2020.0034